BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol 2022. [PMID: 35535555 DOI: 10.2217/fon-2022-0093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Rosa F, Schena CA, Laterza V, Quero G, Fiorillo C, Strippoli A, Pozzo C, Papa V, Alfieri S. The Role of Surgery in the Management of Gastric Cancer: State of the Art. Cancers 2022;14:5542. [DOI: 10.3390/cancers14225542] [Reference Citation Analysis]
2 Zhao Y, Bai Y, Shen M, Li Y. Therapeutic strategies for gastric cancer targeting immune cells: Future directions. Front Immunol 2022;13:992762. [DOI: 10.3389/fimmu.2022.992762] [Reference Citation Analysis]
3 Mukherjee S, Parmar K, Smyth E. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review. Ther Adv Med Oncol 2022;14:175883592211396. [DOI: 10.1177/17588359221139625] [Reference Citation Analysis]